Special Issue

Pediatric Drug Therapy: Safety, Efficacy, and Personalized Medicine

Message from the Guest Editor

Pediatric pharmacotherapy has unique problems owing to children's specific physiological features and developmental stages, which can markedly affect drug metabolism, effectiveness, and safety. Historically, several drugs have been administered to children without thorough pediatric-specific research, resulting in possible dangers. Recent breakthroughs in pharmacogenomics and model-informed precision dosing have facilitated personalized medicine approaches in kids, seeking to customize therapies according to individual genetic profiles and unique requirements. This Special Issue investigates recent research and advancements in pediatric pharmacotherapy, emphasizing safety evaluations, effectiveness assessments, and customized medicine approaches. We solicit submissions that explore subjects including pharmacokinetic and pharmacodynamic research in pediatric populations, the influence of pharmacogenomics on drug response prediction, novel clinical trial methodologies for children, and case studies illustrating the effective application of personalized therapies in pediatric healthcare.

Guest Editor

Prof. Dr. Catherine M. T. Sherwin

- 1. Department of Pediatrics and Department of Pharmacology & Toxicology, Wright State University Boonshoft School of Medicine, Dayton, OH, USA
- 2. Internal Medicine, UWA Medical School, The University of Western Australia, Perth, Australia

Deadline for manuscript submissions

25 November 2025



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/223160

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

